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ABSTRACT
Introduction: Low-density lipoprotein cholesterol (LDL-C) remains a well-established risk factor for
cardiovascular disease (CVD). LDL-C levels are considered primary targets of therapy. A new series of
10 systemic biomolecules, the monoclonal antibodies (mAbs) of proprotein convertase subtilisin/kexin
type 9 (PCSK9), have a higher activity in reducing LDL-C.
Areas covered: The authors critically review the current evidence on the efficacy and safety of
bococizumab, a humanized mAb against PCSK9, which was surprisingly discontinued in November
2016. The pharmacokinetic profile and the biological features of bococizumab vs others mAbs are also
15 discussed. As of now, in adjunct to diet, alirocumab and evolocumab are the only approved PCSK9
mAbs for the treatment of adult patients with severe clinical atherosclerotic CVD already at maximally-
tolerated statin therapy and require additional LDL-C lowering.
Expert opinion: Although discontinued, data from a phase 2b trial show the effectiveness of bococi-
zumab in lowering LDL-C in a similar way to the two available PCSK9 antagonists. However, some
20 peculiar biological characteristics of bococizumab may explain the attenuation of LDL-C lowering over
time, as well as a higher rate of immunogenicity and of injection-site reactions.
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1. Introduction
Hyperlipidemias, multifactorial conditions partly genetically and
partly life habit induced, represent the most important under-
25 lying risk factors for cardiovascular disease [1]. The primary
effort in hypolipidemic drug therapy is focused on lowering
the primary carriers of cholesterol, namely low-density lipopro-
teins (LDLs) [2]. Among drugs primarily reducing  LDL  -choles-
terol (LDL-C), the monoclonal antibodies (mAbs) against
30 proprotein convertase subtilisin/kexin protein 9 (PCSK9), aliro-
cumab and evolocumab, have been approved in the United
States and in the European Union in August 2015 [3]. As of now,
the best characterized activity of secreted PCSK9 is to post  tran-
slationally regulate the number of cell-surface LDL receptors
35 (LDL-R) [4]. The PCSK9 gene, coded on chromosome 1p32.3, is
ubiquitously expressed. It binds to the LDL-R, thus not allowing
the uptake of LDL particles from extracellular milieu into cells
[5]. By this mechanism, PCSK9 raises LDL-C levels.
In adjunct to diet, PCSK9 inhibitors are indicated for the
40 treatment of adult patients with severe clinical atherosclerotic
cardiovascular disease (i.e.  heart attacks or strokes), who are
already at maximally  tolerated statin therapy and requiring
additional LDL-C lowering [6,7]. The efficacy of PCSK9 inhibi-
tors is dramatic and may reach up to 55% LDL-C lowering as
45 monotherapy [8–10] and up to  61% when added to standard
therapy [11,12]. Of note, the currently approved indications
report that heterozygous familial hypercholesterolemic (HeFH)
and homozygous familial hypercholesterolemic (HoFH)
  patients may be treated with evolocumab [13], whereas alir-
50ocumab may be prescribed only to HeFH patients [14].
1.1. Overview of current developments
Alongside with evolocumab (Repatha – Amgen AQ3) and alirocumab
(Praluent – Sanofi and Regeneron Pharmaceuticals), AQ4bococizu-
mab (also called RN316/PF-04950615; Pfizer AQ5) had undergone a
55large Phase 3 program called ‘  Studies of PCSK9 Inhibition and the
Reduction of vascular Events (SPIRE)’ [15]. In a statement issued
on 1  November 2016, Pfizer surprisingly announced discontinua-
tion of global development of bococizumab, its investigational
PCSK9 mAb.
60Furthermore, based on the data from these three com-
pounds, data on the safety and efficacy of the novel agent
RN317 (PF-05335810; Pfizer) have been reported from a Phase
  1 randomized study. This humanized mAb is an engineered
IgG2∆  that binds to PCSK9 with a lower affinity at low pH
65(acidic endosomal compartment) compared to neutral pH
(plasma). The pH-sensitive binding to PCSK9 prolongs the
entity of RN317 half-life extending the duration of LDL-C
reduction over an 85-day dosing interval. RN317 appears to
escape endosomal degradation and, thus, can be recycled and
70potentially reutilized [16].
Safety and efficacy data of LY3015014 (Lilly AQ6) have been
reported in a Phase 2 study [17]. LGT209 (Novartis AQ7) has been
discovered as a lipid lowering agent but licensed to another
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company (CYON) for the treatment of sepsis, whereas RG7652
75 (Roche/Genentech) was discontinued in 2014 [18].
Another approach to a possible antagonism to PCSK9 may
be by RNA interference (ALN-PCSSC – AlynamAQ8 ) [19] whose
single-dose administration led to a rapid and dose-dependent
reduction in plasma PCSK9 protein. Higher doses of ALN-PCS
80 resulted in more prolonged PCSK9 reduction [19]. The treat-
ment was shown to be safe with similar adverse events
between ALN-PCSsc and placebo groups [19].
A similar interference may be obtained with a PCSK9 bind-
ing small molecule (Adnectin; Bristol-Myers Squibb R&D
85 Company),AQ9 for which only animal data are available [20].
Finally, vaccination against PCSK9 represents a potential
approach to reduce the administration to once a year injec-
tions; participants are being recruited to Phase 1 clinical trials
of two vaccine candidates (ATH04A and ATH06A by AFFiRiS).
90 2. Chemistry
Bococizumab (C6414H9918N1722O2012S54) isAQ10 a 145.1 kg/mol
humanized mAb G2Δa, with gamma2 heavy chain (1–444)
[humanized VH (Homo sapiens IGHV1-46*01 (90.80%)-(IGHD)-
IGHJ1*01 L123>T (113)) [8.8.11] (1–118) –  H.  sapiens IGHG2*01
95 (CH1 (119–216), hinge (217–228), CH2 A115>S (327), P116>S
(328, 229–337), CH3 (338–442), CHS (443–444)) (119–444)],
(132-214ʹ)-disulfide with kappa light chain (1ʹ-214ʹ) [huma-
nized V-KAPPA (  H.  sapiens IGKV1-13*02 (91.00%) – IGKJ2*01)
[6.3.9] (1ʹ-107ʹ) –  H.  sapiens IGKC*01 (108ʹ–214ʹ)]; dimer (220–
100 220‘:221–221’:224–224‘:227–227’)-tetrakisdisulfide.
Bococizumab is a humanized mAb against PCSK9; this fea-
ture makes it different from the other two mAbs anti-PCSK9,
alirocumab and evolocumab, both are fully human antibodies.
Although the incidence of immune reactions to mAbs is
105 usually limited (from <1%  to 10%) [21], the immunoreactivity
potential decreases from the first generation of chimeric anti-
bodies to the last series of fully human antibodies [22,23].
Indeed, if compared with chimeric and humanized mAbs,
they generally show reduced immunogenicity [24]. Anti-boco-
110cizumab antibodies were detected in approximately 7% of
treated patients after 24 weeks of administration. One patient
(0.4% of total) also developed a partial reduction of the hypo-
cholesterolemic effect of bococizumab, suggesting a potential
antagonized effect of endogenous antibodies developed dur-
115ing therapy by the immune system [25].
The development of autoantibodies anti  -mAbs has also
been registered with both evolocumab and alirocumab,
although with a lower incidence. In the DESCARTES AQ11study,  2
out of 901 patients  had detectable binding antibodies before
120or at the time of randomization and   1 had transient anti-
evolocumab-binding antibodies after 52 weeks of treatment
[8]. No neutralizing antibodies were observed in any treated
patient [8]. In the LAPLACE-2 AQ12trial, 1899 patients were treated
with evolocumab. Three evolocumab-treated patients were
125positive for binding antibodies before starting treatment. Of
these, one had detectable binding antibodies at the end of the
study. No cases of neutralizing antibodies were reported [26].
By combining all clinical trials, only 0.1% of the patients (7 out
of 4  846 with primary or mixed hypercholesterolemia; and 0
130out of 80 with familial homozygous hypercholesterolemia)
were found positive for anti-evolocumab antibodies.
In a pool of  10 placebo- and active-controlled trials, 4.8% of
patients treated with alirocumab showed anti  drug antibodies
newly detected after initiating treatment, as compared to 0.6%
135of controls. In addition, 1.2% of patients developed neutraliz-
ing antibodies on at least one occasion  and 0.3% exhibited
transient or prolonged loss of efficacy [14].
As such, bococizumab appears to be more immunogenic in
comparison to alirocumab and evolocumab with higher inci-
140dence of developing anti  drug antibodies with neutralizing
activity. However, it must be taken into account that immu-
nogenicity data are highly dependent on the sensitivity and
specificity of the assay. Generally, two-site  (bridging) assays
and radioimmunoassay  are the most common techniques to
145measure immunogenicity [27]. Thus, the lack of standardized
methodologies to measure immunogenicity makes any com-
parative considerations meaningless [27].
It should be noted that, in the case of the most frequently
used monoclonals, i.e. for the treatment of rheumatoid arthritis,
150a very high prevalence of antimonoclonal antibodies has been
reported [28]. Regarding adalimumab, up to 35% of patients
develop circulating antibodies, and the effect of such response
on the therapeutic efficacy is still controversial, with studies that
show no effect [28], and others reported that antidrug antibo-
155dies are significant predictors of no response [29]. Thus, it is
conceivable to conclude that the inability to maintain long-
term and durable cholesterol lowering of bococizumab may
be not exclusively related to the development of anti  drug
antibodies, but other mechanisms could be envisioned.
160A second consideration on the biochemical properties of
bococizumab is related to its IgG isotype. Both bococizumab
and evolocumab are IgG2-λ, whereas alirocumab is an IgG1.
Although the pharmacological implications of these differ-
ences still need to be determined, Yoo  et al. showed that
165antibodies of the human IgG2 subclass can form covalent
dimers in vivo and that IgG2 dimers occur in human serum
Box 1.  Drug summary 
Drug name (generic)AQ25 Bococizumab (RN316/PF-04950615)
Phase (for indication
under discussion)
Discontinued 1  November 2016
Indication (specific to
discussion)
Hypercholesterolemia
Pharmacology description/
mechanism of action
Humanized IgG2Δa monoclonal antibody
that recognizes and binds to the low-
density lipoprotein receptor (LDL-R)-
binding domain of PCSK9, thus
preventing PCSK9-mediated degradation
of LDL-R
Route of administration Subcutaneous injection Q14
Pivotal trial(s) – please
name and describe
NCT01592240; LDL-  cholesterol was
significantly reduced by 53.4 mg/dL at
the dose of 150 mg every  2 weeks and by
44.9 mg/dL at the dose of 300 mg every  4
weeks
2 N. FERRI ET AL.
[30,31]. In the oncological field, the IgG1 has been the most
popular choice for the development of mAbs, mainly due to
the fact that antibodies designed for selective eradication of
170 cancer cells typically require an active isotype that permits
complement activation and effector  -mediated cell killing by
antibody-dependent cell-mediated cytotoxicity.
The IgG1 identity can meet all of the criteria of cell  -
mediated cytotoxicity, i.e. by interacting with the complement
175 factor C1 and with the FcγRI [32], whereas IgG2 does not
possess this property. If the therapeutic goal is neutralization
of a soluble antigen, such as PCSK9, effector functions are less
relevant, and both IgG1 and IgG2 can be utilized.
Nevertheless, the presence of effector functions in alirocumab
180 (IgG1), compared to evolocumab and bococizumab (both
IgG2), still needs to be investigated.
Conversely, the Fcγ receptors are expressed on a wide
variety of cells, including monocytes, macrophages, dendritic
cells, neutrophils, natural killer cells, B cells, and hepatocytes.
185 Thus, based on their innate roles in immune responses, Fcγ
receptors may be involved in the clearance of alirocumab–
PCSK9 complexes from cells opsonized by the mAb [33].
However, the significance of Fcγ receptor-mediated catabo-
lism of mAbs is unclear [33].
190 3. Pharmacodynamics
Bococizumab was selected across 800 mAbs from hybridoma
cell lines, generated by fusing the spleen of wild-type and
PCSK9 null mice immunized with human PCSK9 protein [34].
The antibodies that positively bound PCSK9 by an ELISAAQ13
195 assay were then tested for their effect on the LDL  -R degra-
dation in the liver cell line Huh7 incubated with recombi-
nant PCSK9 [34]. Screening led to the identification of four
antibodies produced by the hybridoma, completely blocking
the activity of PCSK9 on the LDL-R and one of them (J10)
200 showed approximate affinities of 0.3, 0.5, and 2.7 nM with
recombinant human, cynomolgus monkey, and mouse
PCSK9. J10 also completely and dose-dependently inhibited
the binding of human PCSK9 to the LDL-R with an IC  50 of
1 nM [34]. J10 was then engineered into a human IgG2Δ  A
205 and κ chain antibody for further improving its antigen-bind-
ing affinity. From these changes, the J16 antibody contain-
ing the fully human sequenceAQ14 outside of the
complementarity  -determining regions was obtained. J16
binds to a recombinant human PCSK9 molecule with a Kd
210 of approximately 5 pM, a cynomolgus monkey PCSK9 with a
Kd of less than 100 pM, and a mouse PCSK9 with a Kd of
35 pM. J16 completely blocks the human and mouse PCSK9
binding to the LDL-R [34].
The co-crystal structure of the Fab region of J16 and recom-
215 binant PCSK9 showed that the binding site is located mainly
within the catalytic domain of PCSK9, involved in the interac-
tion with the LDL-R. In particular, J16 binds the epitope that
almost perfectly overlaps with the LDL-R EGF-AAQ15 domain bind-
ing site on PCSK9 [35]. Both light and heavy chains mediate
220 the interaction between J16 and PCSK9 and the surface cov-
ered by the antibody is approximately 788 Å2, a larger area
than occupied by the LDL-R EGF-A domain (456 Å2) [34,36].
4. Pharmacokinetics and metabolism
The pharmacokinetic (PK) profile of bococizumab has been
225recently reported [16]. Bococizumab, when administered to
hypercholesterolemic subjects on statin therapy as subcuta-
neous (s.c.) or intravenous (i.v.) injections, shows a slow
absorption. Following single s.c. administrations, Tmax values
equal to 156  and 71 h for doses of 1  and 3 mg/kg  are
230recorded. The maximum concentrations (Cmax) were 11.85 
and 1.824 µg/mL for 1  and 3 mg/kg, respectively. Following
Cmax, a multiphasic decline over time was observed, with
mean terminal t1/2 values of 8.4 ± 2.7 days at the 3 mg/kg
dose. Thus, the half-life of bococizumab appears to be signifi-
235cantly shorter than those of evolocumab and alirocumab (11–
17  and 17–20 days, respectively) [13,14].
As expected for a mAb, the steady  -state volume of distribu-
tion (Vss) of bococizumab is 17.6 l  , i.e. a relatively small value,
due to the limited capacity of mAbs to diffuse into different
240tissues [22]. Absolute bioavailability for bococizumab 1.0 mg/
kg s.c., compared with bococizumab i.v. injection, is 12.5%
[16]. Bioavailability is 44.6% for bococizumab (3.0 mg/kg) s.c.
using dose-normalized AUC AQ16for i.v. (bococizumab 1.0 mg/kg)
as the reference [16].
245A  PK/pharmacodynamic (  PD) model has been developed in
order to characterize the relationship among bococizumab
dose, plasma concentrations, and LDL-C response [37]. The
data for this analysis were derived from a Phase 2b clinical
trial [25]. A two-compartment PK model with parallel first-
250order and Michaelis–Menten kinetics was linked to an indirect
response model describing LDL-C response. Clinical trial simu-
lation indicated a robust reduction in LDL-C  and even greater
LDL-C lowering if no dose titration was implemented in the
Phase 2b study [25]. This analysis clearly indicates that the PK
255profile of bococizumab follows a two-compartment model
with parallel first-order and Michaelis–Menten elimination. A
similar PD profile between alirocumab, evolocumab, and
bococizumab after the biweekly administration indicates a
similar persistence of the antibodies in the circulation.
260Although the PK interactions of mAbs and  small-molecule
drugs are limited, it is tempting to speculate that the clear-
ance of bococizumab, similar to alirocumab and evolocumab,
increases in the presence of the co  administration of statins
[13,14]. Indeed, statins can induce PCSK9 expression facilitat-
265ing the cellular uptake and clearance of mAbs anti  -PCSK9 by
the cells [22]. This interaction was not considered clinically
relevant for both alirocumab and evolocumab. No dose adjust-
ment being required in the case of statin co  administration
[13,14].
2705. Clinical efficacy
5.1. Phase 1 studies
Seven Phase 1 clinical studies have been registered, none of
which as yet published, as a full article, in peer-reviewed
journals. In diet-managed hypercholesterolemic subjects
275(LDL-C ≥ 130 mg/dL), ascending single i.v. administration of
bococizumab (dose range 0.3  –18 mg/kg) resulted in mean
percentage LDL-C reductions from baseline of up to 84%
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(18 mg/kg). As far as adverse events are concerned, s.c. injec-
tions of 2 mL bococizumab (100 or 200 mg) gave  the highest
280 mean pain score of 3.82 ± 7.75 mm (visual analog scale ran-
ging from no pain  [0  ] to 100 mm) [38].
NCT00991159 evaluated safety and tolerability of single,
escalating, i.v. infusions to healthy adults. NCT01243151 eval-
uated the safety and tolerability of repeated doses in volun-
285 teers with hypercholesterolemia. NCT01435382 estimated the
absolute bioavailability of bococizumab in subjects with
hypercholesterolemias, not on lipid-lowering therapy.
NCT02043301 studied the single  -dose PK of bococizumab
after s.c. injection into the abdomen, upper arm, or thigh.
290 NCT02458209 assessed the s.c. PK and PD of bococizumab in
healthy adults by comparing drug substances manufactured at
two different locations and administration via prefilled syringe
vs. prefilled pen. NCT01163851 evaluated the PK and PD of a
single dose of bococizumab in volunteers on stable atorvasta-
295 tin doses; the trial website reports the obtained data.
NCT01163838 was stopped prior to enrollment.
5.2. Phase 2 studies
Before publication of a full manuscript [25], data on Phase 2a
studies were presented in abstract forms; i.e.  in 135 subjects
300 with a mean baseline LDL-C of 123 mg/dL, already at high-
dose statins (atorvatstain or simvastain 40 or 80 mg or rosu-
vastatin 20 or 40 mg), a 12  -week  treatment with 3  and 6 mg/
kg of bococizumab, administered i.v. every 4 weeks, gave LDL-
C reductions of 46% and 56% [38,39].
305 The NCT01592240, a Phase 2 multicenter,   double-blind,
placebo-controlled, dose-ranging trial in 351 adults (299 com-
pleted treatment) with baseline fasting LDL ≥80 mg/dL and
triglycerides ≤400 mg/dL, reported no CVAQ17 events within
6 months. Randomized subjects received every 14 days s.c.
310 placebo or bococizumab 50, 100, or 150 mg, alternatively
every 28 days s.c. placebo or bococizumab 200 or 300 mg.
The trial foresaw a peculiar dose-ranging design in which an
LDL-C fall to ≤25 mg/dL corresponded to a reduction in
bococizumab dose administration. The primary end  point
315was the absolute change in LDL-C from baseline to week 12
after randomization; 14 days bococizumab 150 mg (Q14) and
bococizumab 300 mg (Q28) were the most effective doses.
After placebo-adjustment, LDL-C and TC AQ18were significantly
reduced by 53.4 mg/dL (Figure 1) and by 53.1 mg/dL (Q14)
320and by 44.9 mg/dL and by 45.6 mg/dL (Q28), respectively.
Non-HDL-C AQ19and apolipoprotein (apoB), further markers of CV
risk, were significantly lowered by 55.6  and 32.1 mg/dL (Q14)
and by 48.6  and 28.5 mg/dL (Q28), respectively. ApoB can be
considered as equivalent to non-HDL-C especially in case of
325hypertriglycerid  emias [2]. HDL-C levels were significantly
raised by 6.5% (p = 0.043) in the Q28 arm. Regardless of
doses, median percentage changes in TG AQ20showed a trend wise
AQ21
to reduction. Median percentage reductions of Lp(a) were 9%
and 10.7% at Q14 and Q28, respectively. ApoA-I increments
330were not statistically significant, 6.5% (Q14) and 2.7 (Q28). No
differences were recorded for serious adverse AQ22events across
the placebo and bococizumab arms [25]. Nasopharyngitis and
upper respiratory tract infections were found the most fre-
quently adverse events with no differences between the pla-
335cebo and bococizumab arms; diarrhea, bronchitis, arthralgia,
and injection-site reactions were the others. Seven patients
(2%) discontinued treatment [25].
Overall, the Q14 administration was more effective than the
monthly one, and it has been applied to the Phase 3 studies.
340Notably, after administration of bococizumab, a significant
reduction of LDL-C was observed at week 2 with a gradual
increase in the 2  -week  post-nadir. Similar results were
observed with evolocumab [40] and alirocumab [41], suggest-
ing similar clearance rates among mAbs.
3455.3. Phase 3 studies
These studies were halted after the company evaluation of the
first results of a 52-week trial on the effects of bococizumab in
lowering LDL-C. Pfizer announced the discontinuation of the
late-stage PCSK9 inhibitor by a press release on 1 November
3502016. Specifically, the company’s website reports ‘Pfizer Inc.
announced today the discontinuation of the global clinical
development program for bococizumab; Pfizer has observed
an emerging clinical profile that includes an unanticipated
attenuation of LDL-C lowering over time, as well as a higher
355level of immunogenicity and higher rate of injection-site reac-
tions with bococizumab than shown with the other agents in
this class’ [42].
The SPIRE program was planned to involve more than
30,000 participants worldwide, comprehensive of 6 lipid-low-
360ering studies and 2 cardiovascular outcome trials [43]. All of
these trails were aimed at evaluating efficacy, safety, tolerabil-
ity, magnitude of reduction in atherogenic lipids as well as
reduction in the occurrence of major CV events, namely death
due to CVD, myocardial infarction, stroke, and unstable angina
365requiring urgent revascularization [44].
The following trials were designed to evaluate efficacy of
12-week treatment with bococizumab in lowering LDL-C
(measured with a direct assay)  . SPIRE-HR (NCT01968954)
included 727 hyperlipidemic subjects (primary or mixed
Figure 1. Effect of bococizumab on mean absolute change from baseline in
LDL-C following Q14 and Q28 days administrations. Reproduced by permission
of Elsevier [25].
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370 dyslipidemia) at risk of CV events, receiving maximally toler-
ated statin doses; SPIRE-LDL (NCT01968967) enrolled 2139
hyperlipidemic subjects (fasting LDL-C ≥70 mg/dL and tri-
glyceride ≤400 mg/dL; high or very high risk of incurring a
CV event) on highly effective dose statin; SPIRE-LL
375 (NCT01200514) enrolled 749 hyperlipidemic subjects, treated
with a statin, with fasting LDL-C ≥100 mg/dL and triglycer-
ide ≤400 mg/dL; SPIRE-AI (NCT02458287) enrolling 299 sub-
jects with hyperlipidemia or dyslipidemia (fasting LDL-C
≥70 mg/dL and triglycerides ≤400 mg/dL; treated with a
380 statin)  was aimed at evaluating the effect of bococizumab
given by an auto-injector; SPIRE-FH (NCT01968980) included
370 HeFH patients.
Since LDL-C reduction, obtained with PCSK9 mAbs, has not
been shown yet to reduce clinical CV outcomes, SPIRE-1
385 (NCT01975376) and SPIRE-2 (NCT01975389) were designed with
CV events as their primary outcomes. The enrollment planned to
follow about 28,000 high-risk subjects, both in primary and in
secondary prevention, across a broad range of CV risk.
6. Expert opinion
390 Considering that LDL-C remains the well-established risk factor
for CV disease, one of the main outcomes of the SPIRE program
was to evaluate if the LDL-C reduction rate driven by bococizu-
mab had some additional benefit among statin-treated and
statin-intolerant patients, either in secondary prevention or in
395 high-risk primary prevention [43]. Indeed, the use of PCSK9
mAbs has been, very recently, recommended in (i) very high-
risk patients, i.e.  those requiring more than a 50% reduction in
LDL-C despite already at maximally tolerated statin plus ezeti-
mibe, (ii) in severe familialAQ23 hypercholesterolemia (FH) without
400 ASCVD, requiring a further LDL-C reduction, (iii) and in those,
already belonging to above groups, who are statin intolerant [6].
The overall evaluation of bococizumab for the manage-
ment of hypercholesterolemia indicates an effective mole-
cule with a similar activity as the two available PCSK9
405 antagonists, evolocumab and alirocumab, but with some
differences in the type of selected mAb, i.e.  being a huma-
nized mAb. This characteristic may be linked to the occur-
rence of mAb antibodies, potentially leading to reduced
effectiveness and occurrence of side effects. As pointed
410 out, in the case of mAbs for rheumatoid arthritis, occurrence
of mAb antibodies is not necessarily linked to reduced
effectiveness. This observation, therefore, may lead to a
better understanding of the type of antibody selection to
be carried out, in order to obtain the best cholesterol
415 response with the least immunogenicity. Pfizer could wit-
ness a clinical profile with an unanticipated attenuation of
LDL-C lowering over time, as well as a higher level of
immunogenicity and a higher rate of injection-site reactions
with bococizumab than shown with the other agents in this
420 class [42].
Since occurrence of mAb  -targeted antibodies is not necessa-
rily associated with a reduced PD  response, the observation of
progressive loss of activity of bococizumab  may not only be
consequent to an increased antibody response. No hard data on
425 specific side effects have been, however, provided. Possibly also
for these reasons, trials with bococizumab did not provide any
data on the potential for CV outcome prevention, i.e. as
expected also for other agents with a similar mechanism.
Whether these observations will in some way impact on the
430safety profile of the two available PCSK9 antibodies, i.e.  evolo-
cumab and alirocumab, will require longer and more intensive
monitoring. It is within this context  that the FOURIER trial was
designed to provide important safety data on the long-term
administration of evolocumab and achievement of very low
435LDL-C levels [45]. Particularly, neurocognitive effects of evolocu-
mab are being assessed in the ‘Evaluating PCSK9 Binding
antiBody Influence oN coGnitive HeAlth in High cardiovascUlar
Risk Subjects (EBBINGHAUS)’ trial (NCT02207634).
An interesting PD  aspect of available PCSK9 antagonists is
440the lack of a reducing effect on the hs-C-reactive protein, a
constant finding after statins [46,47]. On the other hand, anti-
bodies can markedly reduce the circulating levels of lipopro-
tein (a) [48,49], versus essentially no effect of statins. Although
the mechanism of the reduction of Lp(a) observed during both
445alirocumab and evolocumab is unclear and debated, a recent
finding has reported how PCSK9 does not significantly mod-
ulate Lp(a) catabolism, but can rather enhance the hepatic
generation of Lp(a) [50]. Of note, Lp(a) reduction driven by
bococizumab (−9% after 150 mg Q14) [25] was lower than that
450observed with alirocumab (−19.5% after 150 mg Q14) [51] and
evolocumab (−32.3% after 140 mg Q12), respectively AQ24[48].
Similar to statins [52], the risk of new-onset diabetes is
likely predictable with the use of PCSK9 inhibitors. Although
randomized controlled trials with PCSK9 antagonists showed
455no evidence of increased development of diabetes [53], PCSK9
genetic variants, associated with lower LDL-C, positively corre-
lated to an increased risk of type  -2 diabetes mellitus [54]. A
19% higher risk for diabetes per 1-mmol/L reduction in LDL-C
was acknowledged (1.19; 95% confidence interval  , 1.02–1.38)
460[55]. Notably, the potentially increased risk of new-onset dia-
betes during treatment with a PCSK9 inhibitor is likely to be
confined to subjects with impaired fasting glucose levels [56].
Finally, the high cost of therapy with PCSK9 inhibitors for
FH or atherosclerotic cardiovascular disease patients should be
465considered. Assuming that the 2015 prices of alirocumab and
evolocumab are around $14,000 per year, the price should be
reduced to $4  536 or less per patient to be cost-effective on
total US healthcare spending [57].
From the failure of the clinical development of bococizu-
470mab, one can potentially conclude that long-term treatment
with PCSK9 inhibitors should be associated with a very low
development of immunogenic mAbs. From available data,
only fully human antibodies seem to be suitable for this
therapy. Moreover, it should bear in mind that the s.c. injec-
475tion of mAbs in the presence of anti  drug antibodies results in
the local formation of immune complexes in the injection site,
reducing the release of the drug into the circulation [27].
The development of pH  -sensitive mAbs  , such as RN317,
appears to be a promising venue, also in view of the stability
480of response, apparently predicting a lower risk of events [16]. In
addition, presently available data indicate that the ideal IgG
isotype should be the IgG1, which is less prone to form dimers
and to precipitate at the injection site. Unfortunately, the cost of
these treatments remains one of the major limiting steps for use
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485 in the general population. Development of classical small mole-
cules with PCSK9-inhibitory activity appears to be more difficult,
but probably an effective and less  -expensive approach for gen-
erating a new class of hypocholesterolemic drugs.
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